Literature DB >> 7243216

Changes in the binocular fixation patterns and the visually evoked potential in the treatment of esotropia with amblyopia.

L M Wilcox, S Sokol.   

Abstract

Using the binocular fixation pattern (BFP) and the visually evoked potential (VEP), thirteen amblyopic patients with comitant, non-accommodative esotropia with an angle range up to 30 delta were studied before and during occlusion therapy. A graded BFP with a stronger preferred fixation could be used to diagnose amblyopia. The BFP, however, showed no significant change with therapy despite improvement in acuity. In contrast, the VEP amplitudes, initially reduced in amblyopia, increased significantly as the vision responded to patching. The VEP was useful in diagnosing strabismic amblyopia and giving a predictive range of acuities.

Entities:  

Mesh:

Year:  1980        PMID: 7243216     DOI: 10.1016/s0161-6420(80)35095-1

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  4 in total

1.  Structural and functional comparison of the persistent and resolved amblyopia.

Authors:  Betul Tugcu; Bilge Araz-Ersan; Ezgi Tuna Erdogan; Hatice Tarakcioglu; Cigdem Coskun; Ulviye Yigit; Sacit Karamursel
Journal:  Doc Ophthalmol       Date:  2013-12-18       Impact factor: 2.379

2.  Pattern visual evoked potential as a predictor of occlusion therapy for amblyopia.

Authors:  Woosuk Chung; Samin Hong; Jong Bok Lee; Sueng-Han Han
Journal:  Korean J Ophthalmol       Date:  2008-12

3.  Characterising the orientation-specific pattern-onset visual evoked potentials in children with bilateral refractive amblyopia and non-amblyopic controls.

Authors:  Tiong Peng Yap; Chi D Luu; Catherine M Suttle; Audrey Chia; Mei Ying Boon
Journal:  Doc Ophthalmol       Date:  2020-09-23       Impact factor: 2.379

4.  Predicting potential acuities in amblyopes: predicting post-therapy acuity in amblyopes.

Authors:  William H Ridder; Michael W Rouse
Journal:  Doc Ophthalmol       Date:  2007-02-20       Impact factor: 1.854

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.